2seventy bio Management

Management criteria checks 1/4

2seventy bio's CEO is Nick Leschly, appointed in May 2021, has a tenure of 2.25 years. total yearly compensation is $6.08M, comprised of 12.8% salary and 87.2% bonuses, including company stock and options. directly owns 1.11% of the company’s shares, worth MX$65.53M. The average tenure of the management team and the board of directors is 1.8 years and 1.8 years respectively.

Key information

Nick Leschly

Chief executive officer

US$6.1m

Total compensation

CEO salary percentage	12.8%
CEO tenure	2.3yrs
CEO ownership	1.1%
Management average tenure	1.8yrs
Board average tenure	1.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Nick Leschly's remuneration changed compared to 2seventy bio's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2023	n/a	n/a	-US$215m
Dec 31 2022	US$6m	US$780k	-US$254m
Sep 30 2022	n/a	n/a	-US$292m
Jun 30 2022	n/a	n/a	-US$284m
Mar 31 2022	n/a	n/a	-US$291m
Dec 31 2021	US$6m	US$751k	-US$292m
Sep 30 2021	n/a	n/a	-US$308m
Jun 30 2021	n/a	n/a	-US$320m
Mar 31 2021	n/a	n/a	-US$222m
Dec 31 2020	US$6m	US$725k	-US$120m

Compensation vs Market: Nick's total compensation ($USD6.08M) is above average for companies of similar size in the MX market ($USD611.44K).

Compensation vs Earnings: Nick's compensation has been consistent with company performance over the past year.

CEO

Nick Leschly (50 yo)

2.3yrs

Tenure

US$6,078,514

Compensation

Mr. Nick Leschly has been a Director of bluebird bio, Inc. since March 2010 and served as its President since September 2010 and as its Chief Executive Officer since September 2010 until 2021. He served as...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Nick Leschly	President	2.3yrs	US$6.08m	1.11% MX$ 65.5m
Philip Gregory	Chief Scientific Officer	1.8yrs	US$2.53m	0.065% MX$ 3.9m
William Baird	Chief Financial Officer	1.8yrs	US$2.44m	0% MX$ 0
Susan Abu-Absi	Chief Technology & Manufacturing Officer	no data	no data	no data
Teresa Jurgensen	Senior VP	no data	no data	no data
Kathleen Wilkinson	Chief People Officer	no data	no data	no data
Jenn Snyder	Senior Vice President of Corporate Affairs	no data	no data	no data
Steven Bernstein	Chief Medical Officer	1.5yrs	no data	no data
Melissa Price	Senior Vice President of Development Operations & Portfolio Strategy	less than a year	no data	no data
Michael Certo	VP & Head of Genome Editing	no data	no data	no data

1.8yrs

Average Tenure

51yo

Average Age

Experienced Management: TSVT *'s management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Nick Leschly	President	2.6yrs	US$6.08m	1.11% MX$ 65.5m
Daniel Lynch	Independent Chairman of the Board	1.8yrs	US$327.57k	0.025% MX$ 1.5m
Marcela Maus	Independent Director	1.8yrs	US$242.42k	0.010% MX$ 610.2k
Denice Torres	Independent Director	1.8yrs	US$330.51k	0.021% MX$ 1.3m
Sarah J. Glickman	Independent Director	1.8yrs	US$253.54k	0.010% MX$ 610.2k
Wei Lin	Independent Director	less than a year	no data	no data

1.8yrs

Average Tenure

57.5yo

Average Age

Experienced Board: TSVT *'s board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

2seventy bio Management

Management criteria checks 1/4

Key information

Recent management updates

2seventy bio, Inc., Annual General Meeting, Jun 10, 2024

2seventy bio, Inc. Announces Board Appointments

2seventy bio, Inc. Announces Executive and Board Changes

2Seventy Bio, Inc. Announces That Chip Baird Is Now Chief Operating Officer Expanding His Responsibilities to Include Finance, Corporate Development, Investor Relations and Corporate Communications as Well as Portfolio and Program/Alliance Management

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

2seventy bio, Inc. to Report Q2, 2024 Results on Aug 07, 2024

2seventy bio, Inc., Annual General Meeting, Jun 10, 2024

2seventy bio, Inc. to Report Q1, 2024 Results on May 15, 2024

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $15 million.

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

2seventy bio, Inc. Announces Board Appointments

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

2seventy bio, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

2seventy bio, Inc. Announces Executive and Board Changes

Bristol Myers Squibb and 2seventy bio, Inc. Announce Results from the Preplanned Final Progression-Free Survival Analysis of KarMMa-3

Bristol Myers Squibb and 2seventy bio, Inc Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Early Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

2seventy bio, Inc. Announces Goodwill Impairment Charges for the Third Quarter Ended September 30, 2023

2seventy bio, Inc. to Report Q3, 2023 Results on Nov 14, 2023

2seventy bio, Inc. Plans to Reduce its Workforce by Approximately 40%

2Seventy Bio, Inc. Announces That Chip Baird Is Now Chief Operating Officer Expanding His Responsibilities to Include Finance, Corporate Development, Investor Relations and Corporate Communications as Well as Portfolio and Program/Alliance Management

2seventy bio, Inc. to Report Q2, 2023 Results on Aug 14, 2023

2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia

First quarter 2023 earnings released: US$1.08 loss per share (vs US$3.20 loss in 1Q 2022)

High number of new and inexperienced directors

High number of new and inexperienced directors

Bristol Myers Squibb and 2Seventy Bio Announce the First Publication and Presentation of Positive Results from KarMMa-3

2Seventy Bio, Inc Announces Resignation of Nicola Heffron as Chief Operating Officer, Effective as of March 10, 2023

High number of new and inexperienced directors

President recently sold Mex$590k worth of stock

2seventy bio, Inc. announced that it has received $19.999996 million in funding from Regeneron Pharmaceuticals, Inc.

High number of new and inexperienced directors

2Seventy Bio, Inc. to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

2Seventy Bio Announces Plans to Initiate KarMMa-9 Study of Abecma (Idecabtagene Vicleucel) in Newly Diagnosed Multiple Myeloma Patients

Second quarter 2022 earnings released: US$2.02 loss per share (vs US$3.60 loss in 2Q 2021)

Bristol Myers Squibb and 2seventy bio, Inc. Announce Topline Results from KarMMa-3

President recently sold Mex$1.8m worth of stock

President recently sold Mex$1.5m worth of stock

High number of new and inexperienced directors

2Seventy Bio, Inc. Announces Resignation of William Sellers to Its Board of Directors

High number of new and inexperienced directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age